CA-ALTIUM-LLC
3.3.2020 05:02:07 CET | Business Wire | Press release
TASKING, the embedded software division of Altium (ASX:ALU), today announced its new multi-core development environment for third-generation AURIX™ microcontrollers from Infineon. This capability will allow TASKING and Infineon automotive customers to optimize performance for multi-core architecture for safety-critical applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302006089/en/
“Infineon and TASKING have a longstanding relationship in expansion of software development tools for Tricore™/AURIX™,” said Ralf Ködel, Director Product Marketing Microcontroller at Infineon, “With this new environment, TASKING provides an innovative one-stop shop solution for our customers.”
This upcoming AURIX™ family of microcontrollers will be prepared for data-hungry automotive applications such as future gateways, domain and zone controllers, engine management, electro-mobility, and advanced driver assistance systems. At the same time these microcontrollers will deliver the safety features, throughput, and power-efficient performance necessary to meet increasing AI computational requirements.
The new TASKING development environment is being developed according to Automotive SPICE® Level 2 standards, with plans for TÜV certification according to ISO 26262 up to ASIL D. This development environment provides compiler support for the new Parallel Processing Unit (PPU) from Synopsys, one of the main enhancements in the next generation AURIX™ family of microcontrollers, in addition to all instruction set architectures used in the next generation AURIX™ TC v1.8.
“These new capabilities from TASKING, empower our automotive customers to make safer traditional and autonomous vehicles, by providing them with a more expansive set of software development tools,” said Franz Maidl, Director Global TASKING Business. “This expansion also reinforces our relationship with Infineon as a partner of choice for Tricore™/AURIX™.”
About TASKING
TASKING is the embedded software division of Altium (ASX:ALU). TASKING development tools are used by automotive manufacturers and the world's largest Tier 1 suppliers to develop embedded microcontroller-based powertrain, body control, and Advanced Driver-Assistance Systems (ADAS) - related applications for both traditional and electric vehicles. These customers and those from adjacent industries, rely on the TASKING development tools to create richer next-generation applications while achieving optimum reliability, safety, and performance.
ABOUT ALTIUM
Altium LLC (ASX:ALU), a global software company headquartered in San Diego, Calif., is accelerating the pace of innovation through electronics. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.
The growing demand for smart and connected products is driving advancements in electronics technology. Design trends are demonstrating the need for minimizing power, reducing package size and energy consumption, and prioritizing high-speed design. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers, from idea to board. Users are at the center of Altium’s R&D and business operations. With its unique Business-to-User approach, Altium is focused on developing software that is easy to use and implement, with solutions that enable innovation and deliver industry-leading user productivity.
Products include Altium Designer®, Altium Concord Pro™, Altium 365®, Altium NEXUS®, CircuitMaker®, CircuitStudio®, Octopart®, and TASKING®. To learn more about Altium, visit www.altium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200302006089/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom